Triple Negative Breast Neoplasms
Conditions
Interventions
investigational material(s)
Generic name etc : Capivasertib
INN of investigational material : -
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational mat
Sponsors
AstraZeneca KK
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed TNBC from most recently collected tumour tissue sample 2. Metastatic or locally recurrent disease; locally recurrent disease most not be amenable to resection with curative intent (patient who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible) 3. ECOG/WHO PS: 0-1 4. Measurable disease according to RECIST 1.1 and/or lytics or mixedbone lesions that can be assessed by CT or MRI in the absence of measurable disease 5. FFPE tumour sample from primary/recurrent cancer
Exclusion criteria
Exclusion criteria: 1. Prior Chemotherapy in the neoadjuvant or adjuvant setting within 6 months from the end of chemotherapy to the date ofrandomization; taxane chemotherapy in the neoadjuvant or adjuvant setting within 12 months from the end of chemotherapy to the start of randomization 2. Prior systematic therapy for inoperable locally advanced or metastatic disease 3. Prior treatment with any of the treatments listed below. Patients are not eligible to enter to enter the study if they have received any of the medications specified below or are unable to meet the cautions and restrictions - AKT, PI3K, and/or mTOR inhibitors - Capivasertib in the present study (ie, any dosing with capivasertib due to previous participation in this study) - Any other chemotherapy, immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents within 3 weeks of the first dose of study treatment. A longer washout may be required for drugs with a long halflife (eg, biologics) as agreed by the sponsor -Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to CYP3A4 inhibition within 1 week prior to the first dose of study treatment 4. Radiotherapy with a wide field of radiation within 4 weeks before the first dose of study treatment (capivasertib/placebo) 5. Pre-existing sensory or motor polyneuropathy grade 2 or less according to NCI CTCAE v5 6. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment 7. Any of the following cardiac criteria at screening: - Mean resting corrected QT interval (QTc) >470 msec obtained from 3 consecutive ECGs - Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block) - Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for Torsades de Pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval - Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) grade 2 or less - Uncontrolled hypotension - SBP <90 mmHg and/or DBP <50 mmHg - Cardiac ejection fraction outside institutional range of normal or <50% (whichever is higher) as measured by echocardiogram (or multiplegated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive). 8. Clinically significant abnormalities of glucose metabolism as defined by any of the following at screening: 9. Patients with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment HbA1c 8.0% (63.9 mmol/mol) or less Inadequate bone marrow reserve or organ function at screening 10. Currently pregnant (confirmed with positive pregnancy test) or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy - | — |
Secondary
| Measure | Time frame |
|---|---|
| safety efficacy pharmacokinetics - | — |
Countries
Asia except Japan, Europe, Japan, Middle East, North America, South America
Outcome results
None listed